89bio Inc (ETNB)
9.16
+0.30
(+3.39%)
USD |
NASDAQ |
May 03, 10:56
89bio Cash from Investing (Quarterly): -63.64M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -63.64M |
| September 30, 2023 | 38.33M |
| June 30, 2023 | -101.81M |
| March 31, 2023 | 4.106M |
| December 31, 2022 | -11.06M |
| September 30, 2022 | -42.06M |
| June 30, 2022 | -7.596M |
| March 31, 2022 | 26.77M |
| December 31, 2021 | 19.09M |
| September 30, 2021 | 17.36M |
| Date | Value |
|---|---|
| June 30, 2021 | -13.88M |
| March 31, 2021 | -15.41M |
| December 31, 2020 | -29.03M |
| September 30, 2020 | -72.00M |
| June 30, 2020 | -5.744M |
| March 31, 2020 | -0.061M |
| December 31, 2019 | -0.111M |
| September 30, 2019 | -0.008M |
| June 30, 2019 | -0.018M |
| March 31, 2019 | -0.002M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-101.81M
Minimum
Jun 2023
38.33M
Maximum
Sep 2023
-13.51M
Average
-5.744M
Median
Jun 2020
Cash from Investing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -362.12M |
| Akero Therapeutics Inc | 12.79M |
| Viking Therapeutics Inc | -459.79M |
| Galectin Therapeutics Inc | -- |
| Terns Pharmaceuticals Inc | 47.23M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -34.29M |
| Cash from Financing (Quarterly) | 162.17M |
| Free Cash Flow | -129.19M |
| Free Cash Flow Per Share (Quarterly) | -0.4244 |
| Free Cash Flow Yield | -19.83% |